Immunogenic peptides and their use in immune disorders
AssigneesLife Sciences Research Partners VZW, Katholieke Universiteit Leuven, K.U.Leuven R&D
InventorJean-Marie Saint-Remy
Life of this patent
Estimating the term…
Abstract
The peptides of the invention comprise (i) a T-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class II major histocompatibility complex (MHC) determinant and recognized by a CD4+ T cell, more specifically, of an allergen or autoantigen, coupled, optionally, through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence. The peptides may be used for the prevention or treatment of immune disorders, more specifically, of allergic disorders or autoimmune diseases. The present invention thus provides methods of treatment or preventing immune disorders by using such peptides.
Claims7
A method of eliciting cytolytic CD4+ T cell activity in an individual, comprising administering to said individual an isolated immunogenic peptide with a length of at most 75 amino acids, derived from an autoantigenic protein involved in an autoimmune disease, wherein said immunogenic peptide comprises a T cell epitope sequence of said autoantigenic protein and a sequence with the motif C—(X)2-C, said sequence with the motif being either adjacent to said epitope sequence, or separated from said epitope sequence by a linker of at most 7 amino acids.
Dependencies are inferred from the claim text.